South San Francisco, CA October 11, 2023 Press Release Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based…
Tag: biopharmaceutical
Newborn Babies With Spinal Muscular Atrophy Benefit from Genentech’s Evrysdi
South San Francisco, CA October 4, 2023 Press Release Majority of Newborn Babies With Spinal Muscular Atrophy (SMA) Treated With Genentech’s Evrysdi Able to Sit Independently After 1 Year of Treatment RAINBOWFISH study met its primary endpoint with 80% of…
Genentech Presenting at the 9th Joint ECTRIMS-ACTRIMS Meeting (European and Americas Committees for Treatment and Research in Multiple Sclerosis)
South San Francisco, CA October 2, 2023 Press Release Genentech to Present New Key Clinical and Real-world Data at ECTRIMS-ACTRIMS 2023 Showcasing Strength of Long-term Outcomes in MS and NMOSD Late-breaking results from Phase III trial of Ocrevus (ocrelizumab) subcutaneous…
Genentech Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer
South San Francisco, CA August 23, 2023 Press Release South San Francisco, CA — August 22, 2023 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that it has been made aware of an…
Genentech to Pay Penalty for Claims of Hazardous Waste Violations at South San Francisco Facility
South San Francisco, CA August 12, 2023 – EPA Press Release 8/8/23 SAN FRANCISCO – Today, the U.S. Environmental Protection Agency announced a settlement with Genentech, a biopharmaceutical manufacturer based in South San Francisco, for claims of hazardous waste violations…
Genentech’s Evrysdi and Types 2 and 3 Spinal Muscular Atrophy Update
South San Francisco, CA March 20, 2023 Press Release New Four-Year Data for Genentech’s Evrysdi Reinforce Long-Term Efficacy and Safety Profile in Some of the Most Severely Affected People With Types 2 and 3 Spinal Muscular Atrophy (SMA) Data…
Newly Approved Life Science Development Exacerbates Housing Imbalance in South San Francisco
October 28th, 2022 – South San Francisco, CA by ESC Correspondent, Allie Saults The picture to the right is an artist’s rendering of another new development approved and planned for 100 E. Grand Ave. at Sylvester Road, which includes two…
Biocom California Statement on New Drug Pricing Legislation
South San Francisco, CA August 8, 2022 Press Release Note: As South San Francisco boasts the recognition of being the birthplace of biotechnology and home to one of the largest consolidations of life science businesses, this press release is important…
Pliant Therapeutics Announces Proposed Public Offering of Common Stock
South San Francisco, CA July 12, 2022 Press Release Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that it has commenced an underwritten public offering of…
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
South San Francisco, CA March 31, 2022 Press Release SKYSCRAPER-02, the first randomized study of tiragolumab in extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival ES-SCLC is a hard-to-treat disease and Tecentriq plus…